Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (281-290 of 491) with videos related to

Pageof 50
Sort By:
International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAF<sup>V600</sup> mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.
Tumori|February 7, 2020
Cell-free DNA <i>BRAF</i> V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysisKatarzyna Kozak, Artur Kowalik, Aleksandra Gos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2020
SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessmentAnna Szumera-Ciećkiewicz, Francesca Bosisio, Paweł Teterycz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2016
Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survivalCharlotte M C Oude Ophuis, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
BMC Cancer|March 24, 2012
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution studyPiotr Rutkowski, Elżbieta Bylina, Anna Klimczak, et al.
Nature Medicine|October 12, 2023
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumorsCésar Serrano, Sara Rothschild, Guillermo Villacampa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Pageof 50

Showing results (281-290 of 491) with videos related to

Sort By:
Pageof 50
International Journal of Cancer|June 9, 2004
Increased cancer risk of heterozygotes with NBS1 germline mutations in PolandJan Steffen, Raymonda Varon, Maria Mosor, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2019
Health-related quality of life in patients with fully resected BRAF<sup>V600</sup> mutation-positive melanoma receiving adjuvant vemurafenibDirk Schadendorf, Anna Maria Di Giacomo, Lev Demidov, et al.
Tumori|February 7, 2020
Cell-free DNA <i>BRAF</i> V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysisKatarzyna Kozak, Artur Kowalik, Aleksandra Gos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2020
SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessmentAnna Szumera-Ciećkiewicz, Francesca Bosisio, Paweł Teterycz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2019
Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanomaCaroline Robert, Keith Flaherty, Paul Nathan, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2016
Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survivalCharlotte M C Oude Ophuis, Alexander C J van Akkooi, Piotr Rutkowski, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
BMC Cancer|March 24, 2012
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution studyPiotr Rutkowski, Elżbieta Bylina, Anna Klimczak, et al.
Nature Medicine|October 12, 2023
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumorsCésar Serrano, Sara Rothschild, Guillermo Villacampa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.
Pageof 50